Simon Farrell 4
4 · Trevi Therapeutics, Inc. · Filed Feb 16, 2023
Insider Transaction Report
Form 4
Simon Farrell
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2023-02-16+100,000→ 100,000 totalExercise: $2.67Exp: 2033-02-15→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]This option was granted on February 16, 2023. The 100,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027.